Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.

Melanoma research - 1 Aug 2022

Rodríguez Castells Marta, Galisteo Lencastre Veiga Carlos, Fernández-Morales Luis Antonio, Ejarque Martínez Clara, Soriano Sánchez Sandra, López Zurita Natalia, Climent Vicente Carla, Andreu Cobo Pablo, Sierra Boadas Marina, García García Yolanda, Seguí Palmer Miquel Àngel

Abstract excerpt

The effect of serine/threonine-protein kinase B-Raf/mitogen-activated protein kinase (BRAF/MEK) inhibitors on the immune system is not clearly described, but rare cases of autoimmune phenomena have been reported. The clinical case we present below is the first report of a necrotizing myopathy related to dabrafenib/trametinib treatment. A 48-year-old man started dabrafenib/trametinib for stage IV BRAF-V600E...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Creatinine
Share to Fever

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Mitogen-Activated Protein Kinase Kinases

Share to Myositis

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 35635528
DOI: 10.1097/CMR.0000000000000831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.PMID 35635528Read ↗

Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody.Semantic proximity Read ↗

Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.Semantic proximity Read ↗

The pathogenesis of anti-signal recognition particle necrotizing myopathy: A ReviewSemantic proximity Read ↗

Clinical Characteristics of Immune-Mediated Necrotizing Myopathy with Autoantibodies Recognizing the Signal Recognition Particle: A Retrospective Study of a Chinese CohortSemantic proximity Read ↗

Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement.Semantic proximity Read ↗

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.Semantic proximity Read ↗

Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study.Semantic proximity Read ↗

Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosisSemantic proximity Read ↗

Immune-mediated statin myopathy.Semantic proximity Read ↗

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.Semantic proximity Read ↗

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report.Semantic proximity Read ↗

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.